person · Reporting owner

Lopatin Uri A

Disclosed activity across 2 companies

Tapewire entity: 110067
SEC CIK: 0001613259

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216	Chief Medical Officer	March 29, 2019	April 02, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ASSEMBLY BIOSCIENCES, INC.

Report date March 29, 2019 · Filed April 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	627,361	Reported balance After 2019-03-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-03-29 · Grant · Acquired 13,750 · Balance 627,361 F1: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023. F2: Total includes 606,111 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69 · Expires 2029-03-29	Direct	27,500	Reported balance After 2019-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-03-29 · Grant · Acquired 27,500 · Balance 27,500 F3: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023.
Common StockSEC Table I · non-derivative	IndirectBy Wife	5,000	Reported balance Holding disclosure · report date 2019-03-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,000

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023.

F2: Total includes 606,111 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person.

F3: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PARDES BIOSCIENCES, INC.

Report date August 31, 2023 · Filed August 31, 2023

Section 16 reporting ended · disclosed 2023-08-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-31 transaction · row 1 1 source row Row 1 · 2023-08-31 · Other · Disposed 5,327,798 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-08-31 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-08-31 · Other · Disposed 351,948 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. F3: The Reporting Person and his spouse are co-trustees of the Lopatin Descendants' Trust (Trust). The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-05-31	Direct	Reported balance After 2023-08-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-31 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2032-01-31	Direct	Reported balance After 2023-08-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-31 · Disposition to issuer · Disposed 421,000 · Balance 0 F5: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time).

F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.

F3: The Reporting Person and his spouse are co-trustees of the Lopatin Descendants' Trust (Trust). The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

F4: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.

F5: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2023 Filed Aug 31, 2023 14:47 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	Disposition to issuerStock Option (Right to Buy) · Derivative	421,000	Not disclosed Strike: $11.32	Not disclosed	Disclosure SEC source: 0001209191-23-047827 · doc4.xml · derivative · entry 4 Lopatin Uri A · CIK 0001613259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 421,000 shares Expires 2032-01-31 F5 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document
August 31, 2023 Filed Aug 31, 2023 14:47 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	Disposition to issuerStock Option (Right to Buy) · Derivative	37,500	Not disclosed Strike: $1.87	Not disclosed	Disclosure SEC source: 0001209191-23-047827 · doc4.xml · derivative · entry 3 Lopatin Uri A · CIK 0001613259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. Read SEC document
August 31, 2023 Filed Aug 31, 2023 14:47 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	OtherCommon Stock	351,948	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-047827 · doc4.xml · nonDerivative · entry 2 Lopatin Uri A · CIK 0001613259 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. F3 · ownership.nature: The Reporting Person and his spouse are co-trustees of the Lopatin Descendants' Trust (Trust). The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document
August 31, 2023 Filed Aug 31, 2023 14:47 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	OtherCommon Stock	5,327,798	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-047827 · doc4.xml · nonDerivative · entry 1 Lopatin Uri A · CIK 0001613259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. Read SEC document
June 01, 2023 Filed Jun 2, 2023 16:09 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (Right to Buy) · Derivative	37,500	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001209191-23-033673 · doc4.xml · derivative · entry 1 Lopatin Uri A · CIK 0001613259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F1 · derivative.exercise_date: Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders. Read SEC document
February 01, 2022 Filed Feb 2, 2022 19:03 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (Right to Buy) · Derivative	421,000	$0.00 Strike: $11.32	$0.00	Disclosure SEC source: 0000899243-22-004212 · doc4.xml · derivative · entry 1 Lopatin Uri A · CIK 0001613259 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,000 Underlying: Common Stock · 421,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over four years from February 1, 2022, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document
March 29, 2019 Filed Apr 2, 2019 20:36 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantStock Option (right to buy) · Derivative	27,500	$0.00 Strike: $19.69	$0.00	Disclosure SEC source: 0001144204-19-017748 · tv517877_4.xml · derivative · entry 3 Lopatin Uri A · CIK 0001613259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2029-03-29 F3 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023. Read SEC document
March 29, 2019 Filed Apr 2, 2019 20:36 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantCommon Stock	13,750	$0.00	$0.00	Disclosure SEC source: 0001144204-19-017748 · tv517877_4.xml · nonDerivative · entry 1 Lopatin Uri A · CIK 0001613259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,361 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023. F2 · balance_after: Total includes 606,111 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person. Read SEC document
September 06, 2018 Filed Sep 7, 2018 20:44 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	SaleCommon Stock	336	$40.01	$13,442.02	Disclosure SEC source: 0001144204-18-048565 · tv502511_4.xml · nonDerivative · entry 2 Lopatin Uri A · CIK 0001613259 · Chief Med. Off., VP Res. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,611 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range. F5 · balance_after: Total includes 606,111 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person. Read SEC document
September 05, 2018 Filed Sep 7, 2018 20:44 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	SaleCommon Stock	15,204	$40.09	$609,546.60	Disclosure SEC source: 0001144204-18-048565 · tv502511_4.xml · nonDerivative · entry 1 Lopatin Uri A · CIK 0001613259 · Chief Med. Off., VP Res. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,947 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.41, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range. F3 · balance_after: Total includes 606,447 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person. Read SEC document
March 29, 2018 Filed Mar 30, 2018 22:29 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $49.14	$0.00	Disclosure SEC source: 0001144204-18-018347 · tv490034_4.xml · derivative · entry 3 Lopatin Uri A · CIK 0001613259 · Chief Med. Off., VP Res. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-29 F3 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2019; and the remaining 75% shall vest in 36 equal monthly installments, with the options becoming fully vested on March 29, 2022. Read SEC document
March 29, 2018 Filed Mar 30, 2018 22:29 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0001144204-18-018347 · tv490034_4.xml · nonDerivative · entry 1 Lopatin Uri A · CIK 0001613259 · Chief Med. Off., VP Res. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,151 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2019; March 29, 2020; March 29, 2021; and March 29, 2022. F2 · balance_after: Total includes 621,651 shares that are held by the Uri Lopatin Revocable Trust for which the reporting person is the trustee and sole beneficiary. Accordingly, these shares are reported as being held directly by the reporting person. Read SEC document
March 29, 2017 Filed Mar 31, 2017 20:11 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $25.34	$0.00	Disclosure SEC source: 0001144204-17-018188 · v463063_4.xml · derivative · entry 1 Lopatin Uri A · CIK 0001613259 · Chief Med. Off., VP Res. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-03-29 F1 · derivative.exercise_date: The options vest over two years as follows: 50% shall vest on the first anniversary of the date of grant, March 29, 2018; and the remaining 50% shall vest in 12 equal monthly installments, with the options becoming fully vested on March 29, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.